A-O Salgado-Peralvo, M Montero-Alonso, N Kewalramani, M Pérez-Sayáns, M-V Mateos-Moreno, M-R Garcillán-Izquierdo
{"title":"单克隆抗体治疗后炎症性肠病患者口腔炎的患病率:一项系统回顾和荟萃分析","authors":"A-O Salgado-Peralvo, M Montero-Alonso, N Kewalramani, M Pérez-Sayáns, M-V Mateos-Moreno, M-R Garcillán-Izquierdo","doi":"10.4317/medoral.25528","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Currently, the most frequently employed therapies in the treatment of inflammatory bowel diseases (IBD), i.e., Crohn's Disease (CD), Ulcerative Colitis (UC) or unclassified IBD (IBD-U) are monoclonal anti-TNFs and anti-integrin therapies, such as vedolizumab (VDZ). Forty-seven per cent of these patients present extra-intestinal manifestations, the second most prevalent being aphthous stomatitis (AS). The present study aims to investigate which of the two therapies is associated with a lower prevalence of AS after treatment.</p><p><strong>Material and methods: </strong>An electronic search of the MEDLINE (via PubMed), Web of Science, SCOPUS, LILACS and OpenGrey databases was carried out. The criteria used were those described by the PRISMA Statement. The search was not temporarily restricted and was updated to January 2022. The quality assessment was analyzed using the JBI Prevalence Critical Appraisal Tool.</p><p><strong>Results: </strong>After searching, 7 studies were included that met the established criteria. Of these, 6 analysed the prevalence of AS in CD patients and 4 in UC. A total of 1,744 patients were analysed (CD=1,477 patients; 84.69%; UC=267; 15.31%). The greatest reduction in AS prevalence was observed after anti-TNF therapy. The effect of these therapies on the prevalence of AS in patients with IBD-U could not be determined.</p><p><strong>Conclusions: </strong>Both biologic therapies achieve a reduction in the prevalence of AS in IBD patients (CD and UC). However, the best results were obtained in patients treated with anti-TNFs, possibly because VDZ is often used in patients who do not respond adequately to previous treatment with anti-TNFs and because of its intestinal specificity.</p>","PeriodicalId":18351,"journal":{"name":"Medicina oral, patologia oral y cirugia bucal","volume":" ","pages":"e588-e599"},"PeriodicalIF":2.2000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648636/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence of aphthous stomatitis in patients with inflammatory bowel disease after the treatment with monoclonal antibodies: a systematic review and meta-analysis.\",\"authors\":\"A-O Salgado-Peralvo, M Montero-Alonso, N Kewalramani, M Pérez-Sayáns, M-V Mateos-Moreno, M-R Garcillán-Izquierdo\",\"doi\":\"10.4317/medoral.25528\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Currently, the most frequently employed therapies in the treatment of inflammatory bowel diseases (IBD), i.e., Crohn's Disease (CD), Ulcerative Colitis (UC) or unclassified IBD (IBD-U) are monoclonal anti-TNFs and anti-integrin therapies, such as vedolizumab (VDZ). Forty-seven per cent of these patients present extra-intestinal manifestations, the second most prevalent being aphthous stomatitis (AS). The present study aims to investigate which of the two therapies is associated with a lower prevalence of AS after treatment.</p><p><strong>Material and methods: </strong>An electronic search of the MEDLINE (via PubMed), Web of Science, SCOPUS, LILACS and OpenGrey databases was carried out. The criteria used were those described by the PRISMA Statement. The search was not temporarily restricted and was updated to January 2022. The quality assessment was analyzed using the JBI Prevalence Critical Appraisal Tool.</p><p><strong>Results: </strong>After searching, 7 studies were included that met the established criteria. Of these, 6 analysed the prevalence of AS in CD patients and 4 in UC. A total of 1,744 patients were analysed (CD=1,477 patients; 84.69%; UC=267; 15.31%). The greatest reduction in AS prevalence was observed after anti-TNF therapy. The effect of these therapies on the prevalence of AS in patients with IBD-U could not be determined.</p><p><strong>Conclusions: </strong>Both biologic therapies achieve a reduction in the prevalence of AS in IBD patients (CD and UC). However, the best results were obtained in patients treated with anti-TNFs, possibly because VDZ is often used in patients who do not respond adequately to previous treatment with anti-TNFs and because of its intestinal specificity.</p>\",\"PeriodicalId\":18351,\"journal\":{\"name\":\"Medicina oral, patologia oral y cirugia bucal\",\"volume\":\" \",\"pages\":\"e588-e599\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648636/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicina oral, patologia oral y cirugia bucal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4317/medoral.25528\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina oral, patologia oral y cirugia bucal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4317/medoral.25528","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:目前,治疗炎症性肠病(IBD),即克罗恩病(CD)、溃疡性结肠炎(UC)或未分类IBD (IBD- u)最常用的治疗方法是单克隆抗tnf和抗整合素治疗,如维多单抗(VDZ)。47%的患者有肠道外表现,第二常见的是口疮性口炎(AS)。本研究旨在探讨两种治疗方法中哪一种与治疗后较低的AS患病率相关。材料和方法:电子检索MEDLINE(通过PubMed)、Web of Science、SCOPUS、LILACS和OpenGrey数据库。所使用的标准是PRISMA声明所描述的标准。搜索并没有暂时限制,而是更新到2022年1月。使用JBI患病率关键评估工具对质量评估进行分析。结果:经检索,纳入7项符合标准的研究。其中,6例分析了CD患者中AS的患病率,4例分析了UC患者中AS的患病率。共分析了1744例患者(CD= 1477例;84.69%;加州大学= 267;15.31%)。抗肿瘤坏死因子治疗后,AS患病率下降幅度最大。这些疗法对IBD-U患者AS患病率的影响尚未确定。结论:两种生物疗法都能降低IBD患者(CD和UC) AS的患病率。然而,在接受抗tnf治疗的患者中获得了最好的结果,这可能是因为VDZ经常用于对先前的抗tnf治疗反应不充分的患者,也可能是因为VDZ具有肠道特异性。
Prevalence of aphthous stomatitis in patients with inflammatory bowel disease after the treatment with monoclonal antibodies: a systematic review and meta-analysis.
Background: Currently, the most frequently employed therapies in the treatment of inflammatory bowel diseases (IBD), i.e., Crohn's Disease (CD), Ulcerative Colitis (UC) or unclassified IBD (IBD-U) are monoclonal anti-TNFs and anti-integrin therapies, such as vedolizumab (VDZ). Forty-seven per cent of these patients present extra-intestinal manifestations, the second most prevalent being aphthous stomatitis (AS). The present study aims to investigate which of the two therapies is associated with a lower prevalence of AS after treatment.
Material and methods: An electronic search of the MEDLINE (via PubMed), Web of Science, SCOPUS, LILACS and OpenGrey databases was carried out. The criteria used were those described by the PRISMA Statement. The search was not temporarily restricted and was updated to January 2022. The quality assessment was analyzed using the JBI Prevalence Critical Appraisal Tool.
Results: After searching, 7 studies were included that met the established criteria. Of these, 6 analysed the prevalence of AS in CD patients and 4 in UC. A total of 1,744 patients were analysed (CD=1,477 patients; 84.69%; UC=267; 15.31%). The greatest reduction in AS prevalence was observed after anti-TNF therapy. The effect of these therapies on the prevalence of AS in patients with IBD-U could not be determined.
Conclusions: Both biologic therapies achieve a reduction in the prevalence of AS in IBD patients (CD and UC). However, the best results were obtained in patients treated with anti-TNFs, possibly because VDZ is often used in patients who do not respond adequately to previous treatment with anti-TNFs and because of its intestinal specificity.
期刊介绍:
1. Oral Medicine and Pathology:
Clinicopathological as well as medical or surgical management aspects of
diseases affecting oral mucosa, salivary glands, maxillary bones, as well as
orofacial neurological disorders, and systemic conditions with an impact on
the oral cavity.
2. Oral Surgery:
Surgical management aspects of diseases affecting oral mucosa, salivary glands,
maxillary bones, teeth, implants, oral surgical procedures. Surgical management
of diseases affecting head and neck areas.
3. Medically compromised patients in Dentistry:
Articles discussing medical problems in Odontology will also be included, with
a special focus on the clinico-odontological management of medically compromised patients, and considerations regarding high-risk or disabled patients.
4. Implantology
5. Periodontology